[[{“value”:”
Canadian company Aurora Cannabis has announced the launch of its first German-cultivated medical cannabis product amid the easing of restrictions in Germany’s medical cannabis market.
Aurora announced this week the launch of its brand, IndiMed, which manufactures medical cannabis products at Aurora’s leading EU-GMP facility in Leuna, Germany.
The first product launched by the IndiMed brand is Island Sweet Skunk, dried flower, sativa, 20% THC, and less than 1 % CBD, which is expected to be available on January 27.
IndiMed product is cultivated under EU- Good Agricultural and Collection Practices (GACP) and EU-GMP (Good Manufacturing Practices) guidelines. These industry standards are applied to medicinal products seeking to be imported into the European Union, ensuring pharmaceutical-grade quality.
Aurora entered Europe in the mid-2010s, acquiring Germany’s Pedanios in 2017 to anchor its presence in the EU. In the late 2010s, it expanded to Italy, Nordic countries, and Poland through an approach of adapting to strict regulations, supplying medical cannabis, and investing in R&D. The company started trading on the NYSE in 2018, under the ticker symbol ACB.
This announcement comes at a favorable moment for Germany’s medical cannabis market, which removed cannabis from controlled substances drugs and legalized recreational cannabis for personal use last year.
Medical cannabis markets benefited from this change in legislation since it eased access to medical cannabis.
North American companies have also begun investing in the German market.
Earlier this month, Canada-based cannabis company High Tide entered the German medical cannabis market by acquiring a 51% stake in Frankfurt-based pharmaceutical company Purecan.
The Growth Of Germany’s Medical Cannabis Market
A report by cannabis company Bloomwell Group published this month puts into perspective the evolution that has taken place in this industry within the last year alone.
With medical cannabis being increasingly used to treat health-related conditions, access is now easier through digital platforms where patients receive physician-supervised treatments manufactured to pharmaceutical standards.
The report identifies a diversification in the strains of medical cannabis dispensed throughout 2024.
Furthermore, prices have been steadily dropping, showing a well-supplied market despite some fluctuations earlier this year, with the gram price falling from €9.27 ($9.72) in January to €8.35 ($8.76) in November. For the first time, a strain was listed at €3.99 ($4.19) per gram.
With the reclassification of medical cannabis as non-narcotic, which triggered an unprecedented increase in prescription numbers, the number of prescriptions given out by pharmacies had risen more than 1,000% by December 2024, higher than in March of the same year, proof that the regulatory changes have caused a sea change in the ways of accessing it.
One of the other interesting trends found in the report is the increasing demand for high levels of THC in strains. By the end of 2024, strains whose THC content is above 25% constitute nearly a third of all prescriptions, while the average THC concentration was at 23.35%.
Niklas Kouparanis, Co-Founder and CEO of Bloomwell Group, said in a press statement that Germany’s cannabis reforms could serve as a model for other European countries.
“We are at the very beginning of a new era,” he said. “Cannabis was a widely used remedy hundreds of years ago. After decades of stigmatization, the German government has ushered in a change in our country that also serves as a model of progressive policies for other European countries.”
A poll conducted after the legalization of recreational cannabis in December 2024 showed that 59% of Germans support full legalization, marking the first increase in support since the cannabis reform took effect in April last year.
“}]] Aurora announced this week the launch of its brand, IndiMed, which manufactures medical cannabis products at Aurora’s leading EU-GMP facility in Leuna, Germany. Read More
